- Mark Zuckerberg and Priscilla Chan joined Neko Health’s $700 million Series C as individual investors, along with Tim Ferriss, Maria Sharapova, Thierry Henry, Jimmy Iovine, and will.i.am.
- Lightspeed Venture Partners and O.G. Venture Partners led the funding round. Daniel Ek and Hjalmar Nilsonne plan to open clinics in New York in 2026.
- This funding comes after a $260 million Series B in January 2025. Neko’s £299 scan has been used in over 100,000 appointments and has a 75% rebooking rate.
Mark Zuckerberg has personally invested in Daniel Ek‘s effort to promote proactive health management, similar to how people manage their Spotify subscriptions. Zuckerberg and Priscilla Chan are individual investors in Neko Health‘s $700 million Series C as the company, co-founded by Ek and Hjalmar Nilsonne, gets ready to open its first US clinics.
Zuckerberg and Chan are investing in Neko as individuals, not through Meta or a venture fund. The main institutional investors are Lightspeed Venture Partners and O.G. Venture Partners.
Returning investors include Atomico, General Catalyst, and Lakestar, while new investors are Liberty City Ventures, Positive Sum, and BDT & MSD. David Ofer from O.G. Venture Partners will join Neko’s board if regulators approve.
Other individual investors are Ari Emanuel, Claudia Schiffer, Sir Matthew Vaughn, Danny Meyer, Jimmy Iovine, Maria Sharapova, Thierry Henry, Tim Ferriss, and will.i.am. They join existing supporters like Alexis Ohanian of Seven Seven Six, Alex Tew and Michael Acton-Smith of Calm, Gary Vaynerchuk, Jessie Inchauspé, Katie Haun, Raj Shamani, Steven Bartlett, Zoë Saldaña and Marco Perego-Saldaña.
Ek and Nilsonne have not said how the $700 million will be divided between US expansion and R&D.
A Spotify founder moves into healthcare
Neko Health opened its first clinic in Stockholm in 2023 and is based in Sweden. It now has clinics in London (Marylebone, Spitalfields, Covent Garden, and Victoria), Manchester, and Birmingham. Tech Funding News reported on Neko’s $260 million Series B in January 2025, which valued the company at $1.8 billion.
Neko offers a 60-minute, radiation-free scan that checks skin, blood, heart, and circulation, with a same-day review by a clinician. The scan costs £299 in the UK and 2,750 Swedish krona (SEK) in Sweden. Neko creates its own scanning hardware, software, and clinical protocols.
In June 2026, the company added wearable integration and body composition analysis and opened a new Stockholm clinic with next-generation devices called Derma-2, Echo-2, and Spectrum-2. These devices provide more detailed and automated data. This new hardware will be available in all Neko clinics soon.
A competitive field with many well-funded rivals
Neko is joining a preventive health sector that has attracted investment. Paris-based Lucis recently raised $20 million in a Series A from Singular, and UK-based Emerald launched with £625,000 to bring health data together through diagnostic centres.
In the US, Prenuvo, which offers whole-body MRI scans, has raised $192 million and brings in about $250 million in annual revenue. Function Health, a US blood-biomarker platform, reached a $2.5 billion valuation in November 2025 after raising $298 million. Superpower, a smaller US competitor that uses partner labs, raised $30 million in a Series A.
While Prenuvo uses MRI and Function Health uses lab panels, Neko stands out by developing its own scanning hardware. The company says this lets it add new detection features faster than competitors who rely on outside suppliers.
“We believe this is one of the most important healthcare companies of our generation, and we’re proud to deepen our partnership as they continue to reimagine prevention,” says Bejul Somaia, global partner at Lightspeed Venture Partners.
“For more than 20 years, I’ve tracked every metric imaginable to optimise health and performance. It’s expensive, complicated, and fragmented. I’ve invested in Neko because they offer beautiful simplicity, and only simplicity scales: you get a high-definition map of your biology in less than 60 minutes, explained by an unhurried doctor, all in one location and for £299,” adds Tim Ferriss, bestselling author and Neko investor.
“This funding is a strong vote of confidence in what we set out to do when we opened our first clinic three years ago: a completely new healthcare experience designed to keep people healthy, catch problems early and help prevent disease before it even starts,” notes Nilsonne.
A £299 scan brings up questions about healthcare equity
More than 350,000 people have joined Neko’s waitlist or signed up for a scan, and over 100,000 in the UK and Sweden have already had one. This shows that demand exceeds current capacity. On average, 75% of members book and pay for their next scan before leaving the clinic.
Neko says that three out of four returning members who had serious conditions flagged are now healthy or have their conditions under control. The company also reports that five of seven key biomarkers improved significantly between a member’s first and second scans.
The data show a mixed picture. At £299 per visit and with no insurance option yet, Neko’s goal to serve more than just the privileged few, as O.G.’s Eyal Ofer said, remains a cash-pay model entering a US market with gaps in healthcare access. Prenuvo and Function Health target the same subscription-based health customers, while Quest and Labcorp could bring lab and insurance scale if they move into sensor-based screening.
Whether Neko becomes the leader its investors hope for, or just the best-funded player in a crowded market, may come down to a question money can’t answer: can a £299 scan be more than a premium service for healthy, worried people?
